In contrast, sodium–glucose cotransporter‐2 (SGLT2) inhibitors show no significant effect on overall stroke risk but consistently provide cardiovascular and renal benefits, including reduced heart failure and kidney events [148]. Here, SLC5A2 is linked to stroke disorder.